CNR1 and colitis: Moreover, treatment of wild-type mice with cannabinoid antagonist SR141716A mimicked the CB1-deficient phenotype, and administration of CB1 receptor agonist HU210, or genetic inhibition of FAAH, protected against DNBS-induced colitis in the mice [135].